Pfizer may up AZ offer; EU would tell UK to keep out of the AZ deal; China eases price controls;

@FiercePharma: Top read on FiercePharmaMarketing Weds: 10 big brands keep pumping out big bucks, with a little help from price hikes. Report | Follow @FiercePharma

@TracyStaton: Popular at FiercePharmaMarketing: Payers fret about the next drug doomsday: Pricey PCSK9 cholesterol meds. More | Follow @TracyStaton

@EricPFierce: CEO says Teva will close at least 11 plants, 15% of its network, and 16 more are being evaluated. Story | Follow @EricPFierce

@CarlyHFierce: Drug ads miss the mark with patients who need treatment the most. Article | Follow @CarlyHFierce

> AstraZeneca ($AZN) shares rose 2% today on reports that Pfizer ($PFE) would up its takeover bid to £53 ($89.90) a share, valuing the U.K. company at $113 billion. Story

> The European Union is unlikely to allow the UK to intervene in Pfizer's ($PFE) proposed takeover of AstraZeneca ($AZN). Story

> China will ease price caps on 283 prescription drugs and 250 types of traditional Chinese medicines over concerns that there could be shortages. Story

> Caraco Pharmaceutical Laboratories, owned by Sun Pharmaceutical, is recalling more than 160,000 bottles of venlafaxine hydrochloride extended release tablets, a generic of Pfizer's ($PFE) Effexor XR. Story

> GlaxoSmithKline ($GSK) director Sir Robert Wilson has stepped down from the board. Report

Medical Device News

@FierceMedDev: Qiagen dials up sales as HPV competition heats up. Article | Follow @FierceMedDev

@VarunSaxena2: Braeburn Pharmaceuticals to clinically test subdermal implant for treatment of opioid dependence. Story via FierceDrugDelivery | Follow @VarunSaxena2

@EmilyWFierce: Biotronik scores FDA approval for MRI-safe pacemaker system. Story | Follow @EmilyWFierce

@MichaelGFierce: Icon's Verisome-delivered cataract inflammation treatment enters PhIII. Release | Follow @MichaelGFierce

> Siemens eyes an IPO to spin off its hearing business. More

> St. Jude's a-fib tech aces trial as FDA awaits. Item

Biotech News

@FierceBiotech: Does Alder's IPO setback signal that the biotech IPO boom is ending? Story | Follow @FierceBiotech

@JohnCFierce: 30% of preclin and PhI R&D devoted to cancer - Early-stage cancer drug pipeline booms as payers dig in for a fight. More | Follow @JohnCFierce

@DamianFierce: Second recent biotech buyout with a built-in CVR, after $FRX's $1.5B deal for $FURX. Article | Follow @DamianFierce

@EmilyMFierce: Glaxo, Sanofi stand ready to supply vaccines amid polio emergency. More from FierceVaccines | Follow @EmilyMFierce

> AbbVie makes a run at early EU OK for hep C cocktail. Item

> Lundbeck is buying Chelsea for $658M, with a just-in-case clause. News

> Pfizer's megamerger pitch undermined by empty promises of the past. More

Pharma Manufacturing News

> B. Braun extends recall of saline solution. Story

> FDA to start dumping low-value drugs refused entry to the U.S. News

> FDA study of generic equivalency includes drug made at banned Wockhardt plant. Piece

> NECC owners agree to pay meningitis victims $70M, insurers kick in $25M. Article

> India pharma industry moves to restore its fallen reputation, flagging exports. More

Vaccines News

> Glaxo, Sanofi ready to supply vaccines amid polio emergency. More

> AstraZeneca merger could bring the vaccines heft Pfizer's been looking for. News

> Parents not always swayed to vaccinate children during disease outbreaks. Pierce

> Sanofi's Shan5 overcomes manufacturing setback to score thumbs up from WHO. Story

> Positive H7N9 data could help Novartis hawk flu vax business. Article

And Finally... A study out of Sweden says that mentally ill people are significantly less likely to be violent if they are taking psychiatric medication. Story (sub. req.)

Suggested Articles

With a brand new approval for Adakveo under its belt, Novartis Sunday flaunted an analysis showing the drug could cut patient hospitalizations by 40%.

BeiGene only just won its first Brukinsa nod in MCL. But it’s already pushing to join the CLL field, and Sunday it rolled out more data.

How long can one infusion of CAR-T drug Yescarta continue helping patients with refractory large B-cell lymphoma? Pretty long, Gilead showed Saturday.